menu search

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive kva12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...

November 3, 2023, 8:01 pm

Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immu...

October 9, 2023, 4:10 pm

Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immun...

October 9, 2023, 12:10 pm

Kineta reports second quarter 2023 financial results and provides corporate update

Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting kva12123 in Advanced Soli...

August 11, 2023, 8:01 pm

Kineta to host key opinion leader event on kva12123: vista as an immuno-oncology target

SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation i...

March 6, 2023, 11:30 am


Search within

Pages Search Results: